Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544639 | 1.00 | DPP8 (0.43) | DPP8DPP9ITGB3ITGA2BCALCRL | |
| SCHEMBL13598863 | 0.84 | MEN1 (0.54) | DPP8DPP9ITGB3ITGA2BMEN1 | |
| SCHEMBL28269379 | 0.84 | TDP1 (0.47) | DPP8DPP9MEN1KMT2AALDH1A1 | |
| SCHEMBL28269377 | 0.84 | TDP1 (0.47) | DPP8DPP9MEN1KMT2AALDH1A1 | |
| SCHEMBL28629697 | 0.82 | EPHX1 (0.48) | DPP8DPP9MEN1KMT2AALDH1A1 | |
| SCHEMBL28618898 | 0.82 | TDP1 (0.46) | DPP8DPP9ITGB3ITGA2BMEN1 | |
| SCHEMBL28457530 | 0.81 | MEN1 (0.45) | DPP8DPP9ITGB3ITGA2BMEN1 | |
| SCHEMBL6792312 | 0.81 | DPP7 (0.46) | DPP8DPP9ITGB3ITGA2BMEN1 | |
| SCHEMBL28581494 | 0.80 | EPHX1 (0.46) | DPP8DPP9ITGB3ITGA2BMEN1 | |
| SCHEMBL19708437 | 0.80 | EPHX1 (0.46) | DPP8DPP9ITGB3ITGA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049577-A1 | CGRP antagonists | CALCRL, CALCR, CALCA | DPP8 3752/4885DPP9 2843/4885ITGB3 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.